Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Current Oncology Reports

Volumn 10, Issue 5, 2008, Pages 379-387

  Ohno, Ryuzo ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ABELSON KINASE; ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; NILOTINIB; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; VINCRISTINE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CYTOGENETICS; CYTOPENIA; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG ANTAGONISM; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; GENOME ANALYSIS; HUMAN; LEUKEMIA REMISSION; LEUKEMOGENESIS; LEUKOCYTE COUNT; LIVER TOXICITY; MICROARRAY ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PROGNOSIS; PROTEIN DOMAIN; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; WHOLE BODY RADIATION; AGED; FEMALE; IMMUNOTHERAPY; LYMPHATIC LEUKEMIA; MALE; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 55749104940     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0059-y     Document Type: Review

References (78)

1. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354: 166-178.
2. Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): Long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99: 863-871.
3. Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia 2002, 16: 1259-1266.
4. Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20: 2464-2471.
5. Hunault M, Harousseau JL, Delain M, et al.: Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004, 104: 3028-3037.
6. Kantarjian H, Thomas D, O'Brien S, et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101: 2788-2801.
7. Thomas X, Boiron JM, Huguet F, et al.: Outcome of treatment in adults with acute lymphoblastic leukemia: Analysis of the LALA-94 trial. J Clin Oncol 2004, 22: 4075-4086.
8. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006, 134-141.
9. Larson RA, Dodge RK, Burns CP, et al.: A five drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85: 2025-2037.
10. The Group Francais de Cytogenetique Hematologique: Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996, 87: 3135-3142.
11. Secker-Walker LM, Prentice HG, Durrant J, et al.: Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA: MRC Adult Leukaemia Working Party. Br J Haematol 1997, 96: 601-610.
12. Ueda T, Miyawaki S, Asou N, et al.: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998, 68: 279-289.
13. Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience. Blood 1999, 93: 3983-3993.
14. Thomas X, Danaila C, Le QH, et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: A single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15: 1811-1822.
15. Gleissner B, Gokbuget N, Bartram CR, et al.: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99: 1536-1543.
16. Hermans A, Heisterkamp N, von Linden M, et al.: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987, 51: 33-40.
17. Chan LC, Karhi KK, Rayter SI, et al.: A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987, 325: 635-637.
18. Clark SS, McLaughlin J, Timmons M, et al.: Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988, 239: 775-777.
19. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247: 1079-1082.
20. Faderl S, Kantarjian HM, Thomas DA, et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000, 36: 263-273.
21. Radich JP: Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001, 15: 21-36.
22. Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005, 118-122.
23. Thomas DA: Philadelphia chromosome-positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007, 435-443.
24. Schrappe M, Arico M, Harbott J, et al.: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92: 2730-2741.
25. Roy A, Bradburn M, Moorman AV, et al.: Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: Results of the Medical Research Council ALL 97 trial. Br J Haematol 2005, 129: 35-44.
26. Barrett AJ, Horowitz MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992, 79: 3067-3070.
27. Stockschlader M, Hegewisch-Becker S, Kruger W, et al.: Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995, 16: 663-667.
28. Sierra J, Radich J, Hansen JA, et al.: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997, 90: 1410-1414.
29. Snyder DS, Nademanee AP, O'Donnell MR, et al.: Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999, 13: 2053-2058.
30. Cornelissen JJ, Carston M, Kollman C, et al.: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001, 97: 1572-1577.
31. Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood 2002, 100: 2357-2366.
32. Esperou H, Boiron JM, Cayuela JM, et al.: A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003, 31: 909-918.
33. Iida H, Sao H, Kitaor K, et al.: Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 2004, 79: 79-84.
34. Goldstone AH, Prentice HG, Durrant J, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993) [abstract]. Blood 2001, 98: 856a.
35. Chao NJ, Blume KG, Forman SJ, Snyder DS: Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995, 85: 3353-3354.
36. Avivi I, Goldstone AH: Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 2003, 31: 623-632.
37. Tanimoto M, Miyawaki S, Ino T, et al.: Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: The ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 1998, 68: 421-429.
38. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344: 1031-1037.
39. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344: 1038-1042.
40. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 2002, 99: 3530-3539.
41. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346: 645-652.
42. Talpaz M, Silver RT, Druker BJ, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002, 99: 1928-1937.
43. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348: 994-1004.
44. Druker BJ, Guilhot F, O'Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355: 2408-2417.
45. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100: 1965-1971.
46. Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly use antileukemic agents. Blood 2001, 97: 1999-2007.
47. Towatari M, Yanada M, Usui N, et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004, 104: 3507-3512.
48. Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24: 460-466.
49. Yanada M, Takeuchi J, Sugiura I, et al.: Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008, 93: 287-290.
50. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with Hyper-CVAD and imatinib mesylate. Blood 2004, 103: 4396-4407.
51. Wassmann B, Pfeifer H, Goekbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006, 108: 1469-1477.
52. de Labarthe A, Rousselot P, Huguet-Rigal F, et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007, 109: 1408-1413.
53. Vignetti M, Fazi P, Cimino G, et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109: 3676-3678.
54. Ottmann OG, Wassmann B, Pfeifer H, et al.: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007, 109: 2068-2076.
55. Delannoy A, Delabesse E, Lheritier V, et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study. Leukemia 2006, 20: 1526-1532.
56. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293: 876-880.
57. Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2: 117-125.
58. Hochhaus A, Kreil S, Corbin AS, et al.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16: 2190-2196.
59. Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112: 831-843.
60. Pfeifer H, Wassmann B, Pavlova A, et al.: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2007, 110: 727-734.
61. Zembutsu M, Yanada M, Hishida A: Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol 2007, 31: 313-322.
62. Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305: 399-401.
63. O'Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib resistant Abl kinase domain mutants. Cancer Res 2005, 65: 4500-4505.
64. Talpaz MP, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354: 2531-2541.
65. Verstovsek S, Golemovic M, Kantarjian H, et al.: AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005, 104: 1230-1236.
66. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354: 2542-2551.
67. Kimura S, Naito H, Segawa H, et al.: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106: 3948-3954.
68. Boschelli DH, Wu B, Ye F, et al.: Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl -3-quinolinecarbonitriles
69. Harrington EA, Bebbington D, Moore J, et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10: 262-267.
70. Giles FJ, Cortes J, Jones D, et al.: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109: 500-502.
71. Shaoguang LI: Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008, 49: 19-26.
72. Ottmann O, Dombret H, Martinelli G, et al.: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 2007, 110: 2309-2315.
73. Dai H, Marbach P, Lemaire M, et al.: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003, 304: 1085-1092.
74. Ottmann OG, Larson LA, Kantarjian HM: Nilotinib in Patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib [abstract]. Blood 2007, 110: 2815.
75. Wassmann B, Pfeifer H, Stadler M, et al.: Early molecular response to posttransplantation imatinib determines out-come in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, 106: 458-463.
76. Anderlini P, Sheth S, Hicks K, et al.: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004, 10: 883-884.
77. Carpenter PA, Snyder DS, Flowers ME, et al.: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109: 2791-2793.
78. Ohno R, Asou N, Ohnishi K: Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003, 17: 1454-1463.